Asarina Pharma: Publication of PMDD Phase IIb study - Redeye
The scientific journal Psychoneuroendocrinology recently published data of Asarina Pharma’s phase IIb study in Sepranolone for PMDD (Premenstrual dysphoric disorder), showcasing ‘significant treatment effect’.
ANNONS
The scientific journal Psychoneuroendocrinology recently published data of Asarina Pharma’s phase IIb study in Sepranolone for PMDD (Premenstrual dysphoric disorder), showcasing ‘significant treatment effect’.
